AUDENTES THERAPEUTICS INC. overview

Astellas Completes Acquisition of Audentes Therapeutics - Combined company positioned to become a global leader in AAV-based genetic medicines, with Audentes to operate as a wholly-owned subsidiary and Center of Excellence for Astellas' newly created Genetic Regulation Primary Focus - Natalie C. Holles appointed President and Chief Executive Officer of Audentes PR Newswire TOKYO and SAN FRANCISCO, Jan. 15, 2020 TOKYO and SAN FRANCISCO , Jan. 15, 2020 /PRNewswire/ -- Astellas Pharma Inc. (TSE:...

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Audentes Therapeutics, Inc. - BOLD PR Newswire NEW YORK, Dec. 6, 2019 NEW YORK , Dec. 6, 2019 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City , is investigating Audentes Therapeutics, Inc. ("Audentes" or the "Company") (Nasdaq: BOLD) relating to the sale of the Company to Astellas Pharma...

SHAREHOLDER ALERT: WeissLaw LLP Investigates Audentes Therapeutics, Inc. PR Newswire NEW YORK, Dec. 3, 2019 NEW YORK , Dec. 3, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Audentes Therapeutics, Inc. ("Audentes" or the "Company") (NASDAQ: BOLD) in connection with the proposed acquisition of the Company by Astellas Pharma Inc. ("Astellas Pharma") (OTC:ALPMY). Under the terms of the acquisition...

AUDENTES ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of BOLD and Encourages Investors to Contact the Firm PR Newswire NEW YORK, Dec. 3, 2019 NEW YORK , Dec. 3, 2019 /PRNewswire/ -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder law firm, has launched an investigation into whether the board members of Audentes Therapeutics, Inc. (NASDAQ: BOLD) breached their fiduciary duties or violated the federal securities laws in connection with the company's proposed sale to...

Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, today announced new positive data from ASPIRO, the clinical trial evaluating AT132 in patients with X-Linked Myotubular Myopathy (XLMTM). The data are being presented today at the 24th International Annual Congress of the World Muscle Society by Dr. James J. Dowling, Hospital for Sick Children, Toronto,...

Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, announced it has granted equity awards that were previously approved by the Compensation Committee of its Board of Directors under the Audentes Therapeutics, Inc. 2018 Equity Inducement Plan, as a material inducement to employment to twenty-one individuals hired by Audentes in September 2019. The equity...

Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, today announced that Natalie Holles, President and Chief Operating Officer, will participate in the following investor conferences in October: Chardan 3rd Annual Genetic Medicines Conference Fireside Chat: Monday, October 7, 2019, at 10:30am ET New York, New York Jefferies Gene Therapy/Editing Summit...

Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, today announced its planned presentations at the 24th International Annual Congress of the World Muscle Society in Copenhagen, Denmark, including new data from ASPIRO, the clinical trial evaluating AT132 in patients with X-linked Myotubular Myopathy. The oral presentation will be given by Dr. James J....